Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTB-268 SAD in healthy participants
NCT07350577Phase 1Completed
- Sponsor
- AltruBio Inc.
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing Biological: ALTB-268 with Placebo (Saline solution) (2 arms). Primary endpoints: Adverse Events at day 71, Infusion Site Assessments at day 71 and 3 more. Started Nov 2025; status: completed.
02
Drugs
leiolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07350577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350577.